All In Biotech

Drug Trial Radar · NCT00059306

Secondary Prevention of Small Subcortical Strokes Trial

Secondary Prevention of Small Subcortical Strokes (SPS3) Trial

Last checked: Nov 19, 2026Latest source record: Apr 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,020 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,020

Actual

Start

Feb 2003

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Lead sponsor
University of British ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Apr 24, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline. On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.

Conditions

  • Cerebrovascular Accident
  • Hypertension

Interventions

  • aspirinDrug

    Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.

  • clopidogrelDrug

    Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.

  • Target of Blood PressureOther

    Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.

  • placeboOther

    an inactive substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evidence of clinically defined ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by non-investigational CT or MRITime frame: Mean follow up of 4 years
  2. Evidence of hemorrhagic stroke; a neurologic deficit associated with intraparenchymal or subarachnoid space lesion on CT/MRI or cerebral hemorrhage demonstrated by surgery or autopsy.Time frame: within mean follow-up of 4 years

Locations

63 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Southern Alabama Stroke Center

    Mobile, Alabama

  • Catholic Healthcare West

    Phoenix, Arizona

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • University of Arizona, Department of Neurology

    Tucson, Arizona

  • University of California San Diego Medical Center

    San Diego, California

  • University of California San Francisco-Fresno

    San Francisco-Fresno, California

  • Denver

    Englewood, Colorado

  • Melbourne

    Melbourne, Florida

  • Miami-University of Miami, Miller School of Medicine

    Miami, Florida

  • Emory University, Grady Health System

    Atlanta, Georgia

  • Mercy Medical Center-Ruan Neurology Clinical Research

    Des Moines, Iowa

  • University of Kentucky, Aging/Stroke Program

    Lexington, Kentucky

  • Suburban Hospital

    Bethesda, Maryland

  • Boston University

    Boston, Massachusetts

  • Wayne State

    Detroit, Michigan

  • Henry Ford Hospital, Department of Neurology

    Detroit, Michigan

  • Berman Center

    Minneapolis, Minnesota

  • Mayo Stroke Center KA-SL-13

    Rochester, Minnesota

  • University of Washington

    Sant Louis, Missouri

  • Tenet Health, St. Louis University

    St Louis, Missouri

  • St. John's Mercy

    St Louis, Missouri

  • Cooper University Hospital

    Camden, New Jersey

  • Buffalo

    Buffalo, New York

  • Helen Hayes Hospital

    Haverstraw, New York

  • Columbia University Medical Center

    New York, New York

  • Rochester General Hospital

    Rochester, New York

  • University of Rochester

    Rochester, New York

  • Wake Forest University, Sciences-Neurology

    Winston-Salem, North Carolina

  • Case Western

    Cleveland, Ohio

  • Metrohealth Medical Center

    Cleveland, Ohio

  • Ohio State University, Division of Stroke

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern

    Dallas, Texas

  • Scurlock Stroke Center

    Houston, Texas

  • University of Texas Health Science Center

    San Antonio, Texas

  • University of Washington

    Seattle, Washington

  • Marshfield Clinic, Department of Neurology

    Marshfield, Wisconsin

  • Medical College of Wisconsin-Neurology

    Milwaukee, Wisconsin

  • Calgary Health

    Calgary, Alberta, Canada

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.